Regionally delivered mesothelin CAR-T with PD-1 blockade
Deliver engineered T cells directly into the chest cavity where mesothelioma grows, and give immunotherapy to keep them working.
Intrapleural mesothelin CAR-T (MSK, Adusumilli) with pembrolizumab produced responses and long survivors in a phase 1 study; regional delivery avoids on-target lung toxicity and improves trafficking.
Pages like this
not linked directly; found by shared links- PersonRaffit Hassan
Shares Mesothelin, Mesothelioma.
- TechnologyCAR-T against stroma: fibroblasts and myeloid cells
Shares Armoured, logic-gated & next-gen CARs, Mesothelioma, CAR-T cell therapy.
- IdeaEngineered immune surveillance: long-lived programmed immune cells that patrol for early cancer
Shares Armoured, logic-gated & next-gen CARs, Cold tumours and the immunosuppressive microenvironment, CAR-T cell therapy.
- PersonChristine E. Brown
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
- PersonPhilip D. Greenberg
Shares Mesothelin, CAR-T cell therapy.
- PersonRenier J. Brentjens
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
- PersonJae H. Park
Shares Memorial Sloan Kettering Cancer Center, CAR-T cell therapy.
- IdeaGD2 CAR-T as consolidation in high-risk neuroblastoma
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.